Brain cancer is one of the more deadly forms of cancer, with an overall five-year survival rate of about 33%. That means roughly two out of three people diagnosed with a brain or nervous system tumor do not survive five years. But that single number obscures enormous variation. Some brain tumors are slow-growing and nearly curable, while others remain among the most lethal diagnoses in medicine.
Why the Type of Tumor Matters More Than the Label
The term “brain cancer” covers dozens of distinct tumor types, and they behave very differently. The World Health Organization grades brain tumors from 1 to 4, with grade 1 being the least aggressive and grade 4 being the most. Grade 1 tumors, like pilocytic astrocytomas (the most common type in children), are often curable with surgery alone and carry a favorable prognosis. Grade 4 tumors are a different story entirely.
Glioblastoma, the most common and aggressive malignant brain tumor in adults, is grade 4. Median survival after diagnosis is 15 to 18 months, and fewer than 10% of patients survive five years. That makes it one of the deadliest cancers of any kind. Other grade 4 tumors, including a group called embryonal tumors, also carry poor prognoses, though the specifics vary by subtype.
Grade 2 and 3 tumors fall in between. Lower-grade astrocytomas with certain favorable genetic features can allow patients to live for many years, sometimes a decade or more, though these tumors often eventually progress to higher grades.
Benign Tumors Are Not Risk-Free
Not all brain tumors are malignant. Meningiomas, which grow from the membranes surrounding the brain, are the most common “benign” brain tumor. Their five-year survival rate is about 92%, and their 10-year survival is around 81%. Those numbers sound reassuring, but they’re actually slightly worse than what you’d expect for a similar group of people without the diagnosis. At 20 years, survival drops to about 53%, compared to an expected 67% in the general population.
Benign tumors can also recur. Meningiomas come back in roughly 18% of cases within five years and 32% within 15 years. Because they grow inside the skull, even non-cancerous tumors can cause serious problems by pressing on brain tissue, and repeat surgeries carry their own risks.
Cancer That Spreads to the Brain
Many brain tumors are not primary brain cancers at all. They’re metastases, meaning cancer that started somewhere else (most often the lung, breast, or skin) and traveled to the brain. These secondary brain tumors are actually more common than primary ones, and their outlook is generally poor. A large 2024 study of over 900 patients found a median survival of 5.9 months after a brain metastasis diagnosis. Patients in poor physical condition who received whole-brain radiation survived a median of only about 2 to 3 months.
Genetic Markers That Shift the Odds
Two molecular features have a major impact on how long someone with a glioblastoma is likely to survive. The first is a change called an IDH mutation, and the second involves a chemical modification to a gene’s control switch (called MGMT promoter methylation) that affects how well the tumor responds to chemotherapy.
Patients whose glioblastomas have both of these favorable markers survive a median of nearly 36 months with standard treatment, more than double the typical glioblastoma timeline. Patients with neither marker survive a median of about 13 to 15 months. These genetic differences are now routinely tested at diagnosis because they so dramatically affect the expected course of the disease. They also influence treatment decisions: tumors with the IDH mutation, paradoxically, may be more resistant to the standard chemotherapy drug, while those with the MGMT modification respond better to it.
How Brain Cancer Causes Death
Understanding what makes brain cancer fatal helps explain why it’s so difficult to treat. A study of over 150 patients with high-grade brain tumors found that 77% died from direct tumor progression, meaning the cancer grew to a point where the brain could no longer function. As the tumor expands, it compresses surrounding tissue, disrupts critical functions, and eventually leads to a decline in consciousness and organ control.
The remaining causes of death included infection (12.5%, most commonly pneumonia from difficulty swallowing), seizures (5.3%), bleeding within the tumor (3.3%), and dangerous brain swelling (2.6%). Blood clots in the lungs accounted for another 2.6%. In many cases, multiple complications overlapped. Unlike cancers that spread widely throughout the body, brain cancer typically kills through local destruction of the organ it starts in.
Newer Treatments and What They Add
Standard treatment for glioblastoma has long been surgery followed by radiation and chemotherapy. In recent years, a device-based therapy that delivers alternating electric fields to the scalp (called tumor treating fields) has shown meaningful survival benefits. In a randomized trial published in JAMA, patients who used this therapy alongside chemotherapy survived a median of 20.9 months, compared to 16.0 months for those on chemotherapy alone. That’s roughly a five-month improvement, which is significant for a cancer this aggressive. The benefit held across age groups and regardless of molecular markers.
Still, even with the best available treatments and the most favorable tumor genetics, glioblastoma remains incurable in the vast majority of cases. For lower-grade tumors, the picture is more hopeful, and many patients live years or even decades with careful monitoring and timely intervention.
Putting the Numbers in Context
Globally, brain and central nervous system cancers caused more than 250,000 deaths in 2020, with an age-adjusted mortality rate of about 3 per 100,000 people. That places brain cancer 12th among all cancers for total deaths, far behind lung, liver, and colorectal cancers in raw numbers. But its ratio of deaths to new diagnoses is unusually high: of roughly 308,000 new cases that year, over 80% resulted in death. Few other cancers convert from diagnosis to death at that rate.
The 33% overall five-year survival rate for brain cancers is pulled upward by the inclusion of slower-growing and benign tumors. For malignant tumors alone, the outlook is considerably worse, and for glioblastoma specifically, it remains one of the grimmest prognoses in oncology. Your individual outlook depends heavily on tumor type, grade, molecular features, age, and overall health, making a conversation with a neuro-oncologist far more informative than any general statistic.